Nothing Special   »   [go: up one dir, main page]

EA200000453A1 - Композиции нерастворимого инсулина - Google Patents

Композиции нерастворимого инсулина

Info

Publication number
EA200000453A1
EA200000453A1 EA200000453A EA200000453A EA200000453A1 EA 200000453 A1 EA200000453 A1 EA 200000453A1 EA 200000453 A EA200000453 A EA 200000453A EA 200000453 A EA200000453 A EA 200000453A EA 200000453 A1 EA200000453 A1 EA 200000453A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acylated
insulin
compositions
nph
present
Prior art date
Application number
EA200000453A
Other languages
English (en)
Inventor
Марк Лоренс Брэдер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200000453A1 publication Critical patent/EA200000453A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к нерастворимым композициям, содержащим ацилированные протеины, выбранные из группы, состоящей из ацилированного инсулина, ацилированного аналога инсулина и ацилированного проинсулина, а также к их готовым формам. Эти готовые формы пригодны для парентеральной доставки или для других способов доставки пациенту для длительного контроля за уровнями глюкозы в крови. Более конкретно, настоящее изобретение относится к композициям, включающим комплекс ацилированного протеина с цинком, протамин и фенольное соединение, так что получаемые микрокристаллы аналогичны нейтральной кристаллической форме протамин Hagedorn (NPH) инсулина. Неожиданно было обнаружено, что композиции таких ацилированных протеинов обладают терапевтически превосходными фармакокинетиками при выделении после подкожного введения, и более длительной и благоприятной глюкодинамикой, нежели доступные в настоящее время коммерческие препараты NPH инсулина. При этом кристаллы настоящего изобретения сохраняют преимущества NPH кристаллов, их более легко повторно суспендировать, и они могут смешиваться с растворимыми инсулинами.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000453A 1997-10-24 1998-10-22 Композиции нерастворимого инсулина EA200000453A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6310497P 1997-10-24 1997-10-24
US8893098P 1998-06-11 1998-06-11
PCT/US1998/022434 WO1999021578A1 (en) 1997-10-24 1998-10-22 Insoluble insulin compositions

Publications (1)

Publication Number Publication Date
EA200000453A1 true EA200000453A1 (ru) 2000-10-30

Family

ID=26743043

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000453A EA200000453A1 (ru) 1997-10-24 1998-10-22 Композиции нерастворимого инсулина

Country Status (21)

Country Link
US (3) US6268335B1 (ru)
EP (1) EP1039920A4 (ru)
JP (2) JP2001521006A (ru)
KR (1) KR20010024556A (ru)
CN (1) CN1276731A (ru)
AR (1) AR020047A1 (ru)
AU (2) AU1111799A (ru)
BR (1) BR9813111A (ru)
CA (2) CA2306905A1 (ru)
CO (1) CO4970769A1 (ru)
EA (1) EA200000453A1 (ru)
HR (1) HRP20000236A2 (ru)
HU (1) HUP0004169A3 (ru)
ID (1) ID24890A (ru)
IL (1) IL134901A0 (ru)
NO (1) NO20002038L (ru)
PE (1) PE123799A1 (ru)
PL (1) PL340255A1 (ru)
SV (1) SV1998000125A (ru)
TR (1) TR200001050T2 (ru)
WO (2) WO1999021573A1 (ru)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20020155614A1 (en) * 2001-02-21 2002-10-24 Tomlinson Andrew J. Peptide esterification
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1432430A4 (en) * 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP1429731B1 (en) * 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
AU2002346491A1 (en) * 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
US20050014679A1 (en) * 2001-12-20 2005-01-20 Beals John Michael Insulin molecule having protracted time action
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
JP2006519791A (ja) * 2003-03-13 2006-08-31 ノボ　ノルディスク　アクティーゼルスカブ 新規なｎｐｈインスリン製剤
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
JP2007520441A (ja) * 2003-07-25 2007-07-26 コンジュシェム，インコーポレイティド 持続性インスリン誘導体及びその方法
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
EP1773878B1 (en) 2004-07-19 2015-03-04 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
EP1863840A1 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2023947A4 (en) * 2006-05-10 2009-11-25 Smithkline Beecham Corp COMPOSITION AND METHOD IMPROVING THE CELL PERMEABILITY OF A COMPOUND
WO2007135118A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
KR101729986B1 (ko) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
JP5730569B2 (ja) * 2007-08-15 2015-06-10 ノボ・ノルデイスク・エー／エス アシル及びアルキレングリコール部分を有するインスリンアナログ
PL2203181T3 (pl) 2007-10-16 2018-07-31 Biocon Limited Podawana doustnie stała kompozycja farmaceutyczna i jej sposób
WO2009087081A2 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil
AU2009203810B2 (en) * 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2009129250A2 (en) * 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
JP2011521621A (ja) * 2008-04-22 2011-07-28 ケイス、ウエスタン、リザーブ、ユニバーシティ アイソフォーム特異的インスリン類似体
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
SG173112A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Conjugate based systems for controlled drug delivery
US20100198188A1 (en) * 2009-02-05 2010-08-05 Abbott Diabetes Care Inc. Devices and Methods for Metering Insoluble Active Agent Particles
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
EP2451472A1 (de) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Hitze- und schüttelstabile insulinzubereitungen
TW201113032A (en) * 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
PL3345593T3 (pl) 2009-11-13 2024-04-08 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę
UY33026A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
RU2012123642A (ru) * 2009-12-11 2014-01-20 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
MX337549B (es) 2010-06-23 2016-03-10 Novo Nordisk As Derivados de insulina que contienen enlaces disulfuro adicionales.
SI2611458T1 (sl) 2010-08-30 2017-01-31 Sanofi-Aventis Deutschland Gmbh Uporaba AVE0010 za izdelavo zdravila za zdravljenje sladkorne bolezni tipa 2
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103596584B (zh) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
DK2750699T3 (en) 2011-08-29 2015-10-26 Sanofi Aventis Deutschland A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2014012096A (es) 2012-04-11 2014-11-21 Novo Nordisk As Formulaciones de insulina.
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
AU2014247167B2 (en) 2013-04-03 2018-11-22 Sanofi Treatment of diabetes mellitus by long–acting formulations of insulins
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
HUE036702T2 (hu) 2013-10-07 2018-07-30 Novo Nordisk As Inzulinanalóg új származéka
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CA2932875A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN106794225A (zh) * 2014-08-11 2017-05-31 奥尔巴尼医学院 肉豆蔻酰化的瘦素相关肽及其用途
CA2961037A1 (en) 2014-10-06 2016-04-14 Case Western Reserve University Biphasic single-chain insulin analogues
DK3229828T5 (da) 2014-12-12 2024-10-14 Sanofi Aventis Deutschland Formulering med fast forhold mellem insulin glargin og lixisenatid
CN105884879A (zh) * 2015-01-26 2016-08-24 漳州博欣生物技术有限公司 一种胰岛素类似物的化学合成方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
RU2018107727A (ru) * 2015-08-25 2019-10-01 Ново Нордиск А/С Новые производные инсулина и их медицинские применения
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
EP3509625A1 (en) 2016-09-06 2019-07-17 Chemical & Biopharmaceutical Laboratories of Patras S.A. Proinsulin derivatives
WO2018104346A1 (en) 2016-12-05 2018-06-14 Nuritas Limited Compositions comprising peptide wkdeagkplvk
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
CA3046583A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US20200147215A1 (en) * 2017-04-24 2020-05-14 Simon H. Friedman Drug conjugates with photocleavable solubility modulators
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
CN112512534A (zh) * 2018-05-14 2021-03-16 艾伊拉米治疗有限公司 用于回溶为高浓度液态溶液的胰岛素制剂
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20210102347A (ko) 2018-12-11 2021-08-19 사노피 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
KR102427426B1 (ko) 2019-12-11 2022-08-01 노보 노르디스크 에이/에스 신규한 인슐린 유사체 및 이의 용도
IL296804A (en) 2020-03-31 2022-11-01 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
EP4149516A4 (en) * 2020-05-15 2024-11-13 Eli Lilly and Company LONG-ACTING ACYLATED INSULIN COMPOUNDS
MX2023005935A (es) 2020-11-19 2023-05-29 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina.
WO2022125587A1 (en) * 2020-12-07 2022-06-16 Case Western Reserve University Acylated single-chain insulin analogues
IL317049A (en) 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US3060093A (en) 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3865325A (en) 1971-07-02 1975-02-11 Dylaker Computer Systems Inc Flexible tape reel
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
US4183849A (en) 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
JPS55138391A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
DE3101382A1 (de) 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
JPS58501455A (ja) 1981-09-15 1983-09-01 ノルデイスク　インシユリンラボラトリユ−ム 人インシユリンまたはそのｂ−３０エステルの製造法
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
JPH03506023A (ja) 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
ES2130428T3 (es) 1993-06-21 1999-07-01 Novo Nordisk As Cristales de insulina asp-b28.
ES2163451T3 (es) * 1993-09-17 2002-02-01 Novo Nordisk As Insulina acilada.
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
EP0871665B1 (en) * 1995-03-17 2003-07-23 Novo Nordisk A/S Insulin derivatives
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
PL188736B1 (pl) 1996-06-20 2005-04-29 Novo Nordisk As Wodny preparat insuliny oraz sposób jego przygotowania
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
DE69829953T2 (de) 1997-02-07 2006-03-02 Novo Nordisk A/S Kristallisation von proteinen
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.

Also Published As

Publication number Publication date
IL134901A0 (en) 2001-05-20
US20010036916A1 (en) 2001-11-01
EP1039920A4 (en) 2003-05-28
EP1039920A1 (en) 2000-10-04
SV1998000125A (es) 1999-05-24
TR200001050T2 (tr) 2000-08-21
JP2001521006A (ja) 2001-11-06
CA2306877A1 (en) 1999-05-06
CO4970769A1 (es) 2000-11-07
AU747926B2 (en) 2002-05-30
US6465426B2 (en) 2002-10-15
KR20010024556A (ko) 2001-03-26
CN1276731A (zh) 2000-12-13
CA2306905A1 (en) 1999-05-06
WO1999021578A1 (en) 1999-05-06
PL340255A1 (en) 2001-01-29
HUP0004169A2 (hu) 2001-05-28
US6268335B1 (en) 2001-07-31
HUP0004169A3 (en) 2001-06-28
AU1111799A (en) 1999-05-17
ID24890A (id) 2000-08-31
HRP20000236A2 (en) 2001-02-28
AU1116699A (en) 1999-05-17
US20020082199A1 (en) 2002-06-27
NO20002038D0 (no) 2000-04-18
NO20002038L (no) 2000-06-26
WO1999021573A1 (en) 1999-05-06
PE123799A1 (es) 1999-12-13
BR9813111A (pt) 2000-08-15
JP2001521004A (ja) 2001-11-06
AR020047A1 (es) 2002-04-10

Similar Documents

Publication Publication Date Title
EA200000453A1 (ru) Композиции нерастворимого инсулина
EP0132769B1 (de) Pharmazeutisches Mittel zur Behandlung des Diabetes mellitus
EA200000708A1 (ru) Нерастворимые композиции, применяемые для регулирования концентрации глюкозы в крови
JP2606915B2 (ja) 新規インシュリン誘導体
EP0132770B1 (de) Neue Insulin-Derivate, Verfahren zu deren Herstellung und deren Verwendung sowie pharmazeutische Mittel zur Behandlung des Diabetes mellitus
KR880001701A (ko) 신규한 펩티드
BG61611B1 (bg) Ацилиран инсулин
EP0055945A3 (en) Human proinsulin and analogs thereof and method of preparation by microbial polypeptide expression and conversion thereof to human insulin
AU590896B2 (en) Improved formulations for recombinant beta-interferon
DD244345A5 (de) Neue peptide
CA2006818A1 (en) Insulin derivatives, a process for the preparation thereof, the use thereof and a pharmaceutical formulation containing them
WO1994012219A3 (en) Modified insulin-like growth factors
CA2207078A1 (en) Insulin derivatives with increased zinc binding
CA2399187A1 (en) Kahalalide compounds
US5028587A (en) Mixed crystals of insulin and insulin derivatives
JPH05503940A (ja) 新規インスリン組成物
JP3131215B2 (ja) 新規インスリン誘導体
US20040242460A1 (en) Stabilized acylated insulin formulations
EP0228192A3 (en) Renin-inhibitory oligopeptides, their preparation and use
CA1229588A (en) Process for the preparation of insulin derivatives
WO1997014430A1 (en) Use of thioethers as antioxidant for peptides and proteins and compositions containing the thioethers
AU6756287A (en) Nicorandil-containing preparation for injection
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
IE802224L (en) Cyclic hexapeptide somatostatin
EP0194901A3 (en) Isoprenoidamine derivatives, compositions containing them, their preparation, and their use